Top

Osteoporosis International

Published in:

Open Access 01-02-2010 | Original Article

Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur

Authors: M. Tezval, E. K. Stuermer, S. Sehmisch, T. Rack, A. Stary, M. Stebener, F. Konietschke, K. M. Stuermer

Published in: Osteoporosis International | Issue 2/2010

Abstract

Summary

We have examined the changes induced in the trochanteric region of femur of ovariectomized rat after administration of estradiol and p.arathyroid hormone. We have developed a reproducible biomechanical test and produced trochanteric fractures to evaluate stiffness and strength of this region in addition to histomorphometry.

Introduction

We investigated the short-term effects of parathyroid hormone (PTH) and estrogen (E) on the strength of the rat trochanteric region in a new mechanical test.

Methods

Forty-four 3-month-old female Sprague–Dawley rats were ovariectomized and 8 weeks later treated with soy-free diet (C), daily applications of orally supplied E (0.5 mg/kg food) or subcutaneously injected PTH (0.014 mg/kg), for 5 weeks, and an additional untreated group was added as sham-operated. The femurs were examined for biomechanical and histomorphometric changes.

Results

Our new mechanical test was validated in a right–left comparison. The PTH treatment induced significantly superior biomechanical results (F _max = 225.3 N, stiffness = 314.9 N/mm) compared to E (F _max = 182.9 N, stiffness = 237.2 N/mm), C (F _max = 166.03 N, stiffness = 235.56 N/mm), and sham (F _max = 192.1 N, stiffness = 267.2 N/mm). Animals of the PTH group demonstrated a significantly improved trabecular bone structure and area (75.67%) in comparison to the E (61.04%) and C (57.18%) groups.

Conclusion

Our new biomechanical test is valid and produces trochanteric fracture. Our results show that the short-term antiosteoporotic effects of PTH are in the trochanteric region of ovariectomized rat superior to E.

Sliwinski L, Folwarczna J, Janiec W, Grynkiewicz G, Kuzyk K (2005) Differential effects of genistein, estradiol and raloxifene on rat osteoclasts in vitro. Pharmacol Rep 57:352–359PubMed

Burger H (2003) Hormone replacement therapy in the post-Women's Health Initiative era. Report of a meeting held in Funchal, Madeira, February 24–25, 2003. Climacteric 6(Suppl 1):11–36PubMed

Wuttke W, Jarry H, Westphalen S, Christoffel V, Seidlova-Wuttke D (2002) Phytoestrogens for hormone replacement therapy? J Steroid Biochem Mol Biol 83:133–147CrossRefPubMed

Eriksen EF (2002) Primary hyperparathyroidism: lessons from bone histomorphometry. J Bone Miner Res 17(Suppl 2):N95–N97PubMed

Matsumoto T, Shiraki M, Hagino H, Iinuma H, Nakamura T (2006) Daily nasal spray of hPTH(1–34) for 3 months increases bone mass in osteoporotic subjects: a pilot study. Osteoporos Int 17:1532–1538CrossRefPubMed

Gonnelli S, Martini G, Caffarelli C, Salvadori S, Cadirni A, Montagnani A, Nuti R (2006) Teriparatide's effects on quantitative ultrasound parameters and bone density in women with established osteoporosis. Osteoporos Int 17:1524–1531CrossRefPubMed

Partridge NC, Li X, Qin L (2006) Understanding parathyroid hormone action. Ann N Y Acad Sci 1068:187–193CrossRefPubMed

Ejersted C, Andreassen TT, Nilsson MH, Oxlund H (1994) Human parathyroid hormone(1–34) increases bone formation and strength of cortical bone in aged rats. Eur J Endocrinol 130:201–207CrossRefPubMed

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMed

10.

Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH (2005) Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:1905–1911CrossRefPubMed

11.

Ishihara A, Sasaki T, Debari K, Furuya R, Kawawa T, Ramamurthy NS, Golub LM (1999) Effects of ovariectomy on bone morphology in maxillae of mature rats. J Electron Microsc (Tokyo) 48:465–469

12.

Thompson DD, Simmons HA, Pirie CM, Ke HZ (1995) FDA Guidelines and animal models for osteoporosis. Bone 17:125S–133SCrossRefPubMed

13.

Wronski TJ, Lowry PL, Walsh CC, Ignaszewski LA (1985) Skeletal alterations in ovariectomized rats. Calcif Tissue Int 37:324–328CrossRefPubMed

14.

Zhang G, Qin L, Shi Y, Leung K (2005) A comparative study between axial compression and lateral fall configuration tested in a rat proximal femur model. Clin Biomech (Bristol, Avon) 20:729–735CrossRef

15.

Sturmer EK, Seidlova-Wuttke D, Sehmisch S, Rack T, Wille J, Frosch KH, Wuttke W, Sturmer KM (2006) Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res 21:89–96CrossRefPubMed

16.

Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef

17.

Bagi CM, Wilkie D, Georgelos K, Williams D, Bertolini D (1997) Morphological and structural characteristics of the proximal femur in human and rat. Bone 21:261–267CrossRefPubMed

18.

Mosekilde L, Danielsen CC, Gasser J (1994) The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1–38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology 134:2126–2134CrossRefPubMed

19.

Bagi CM, Ammann P, Rizzoli R, Miller SC (1997) Effect of estrogen deficiency on cancellous and cortical bone structure and strength of the femoral neck in rats. Calcif Tissue Int 61:336–344CrossRefPubMed

20.

Mukherjee M, Das AS, Das D, Mukherjee S, Mitra S, Mitra C (2006) Effects of garlic oil on postmenopausal osteoporosis using ovariectomized rats: comparison with the effects of lovastatin and 17beta-estradiol. Phytother Res 20:21–27CrossRefPubMed

21.

Shen V, Birchman R, Xu R, Otter M, Wu D, Lindsay R, Dempster DW (1995) Effects of reciprocal treatment with estrogen and estrogen plus parathyroid hormone on bone structure and strength in ovariectomized rats. J Clin Invest 96:2331–2338CrossRefPubMed

22.

Oxlund H, Ortoft G, Thomsen JS, Danielsen CC, Ejersted C, Andreassen TT (2006) The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment. Bone 39:244–252CrossRefPubMed

23.

Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P (2007) Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk—a meta-analysis. Osteoporos Int 18:45–57CrossRefPubMed

24.

Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853CrossRefPubMed

Title: Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur
Authors: M. Tezval
E. K. Stuermer
S. Sehmisch
T. Rack
A. Stary
M. Stebener
F. Konietschke
K. M. Stuermer
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 2/2010
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0941-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2010

Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures

Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study

Assessment of trabecular and cortical architecture and mechanical competence of bone by high-resolution peripheral computed tomography: comparison with transiliac bone biopsy

Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease

Association between circulating osteoprogenitor cell numbers and bone mineral density in postmenopausal osteoporosis

Urinary levels of pentosidine and the risk of fracture in postmenopausal women: the OFELY study